In a phase 3 trial, the investigational dihydropyridine calcium antagonist clevidipine demonstrated less pronounced perioperative blood pressure excursions compared with other intravenous antihypertensive agents in patients undergoing cardiac surgery.
In a phase 3 trial, the investigational dihydropyridine calcium antagonist clevidipine demonstrated less pronounced perioperative blood pressure excursions compared with other intravenous antihypertensive agents in patients undergoing cardiac surgery.
The results of the trial were presented at the 56th Annual Scientific Session of the American College of Cardiology (ACC).
The Evaluation of Clevidipine in the Postoperative Treatment of Hypertension Assessing Safety Events (ECLIPSE) study consisted of 3 open-label trials involving 1,964 cardiac surgery patients. In the studies, patients were randomized to clevidipine, nitroglycerin, sodium nitroprusside, or nicardipine. Patients' blood pressures were monitored beginning just before surgery, and the assigned antihypertensive drug was administered if blood pressure increases were deemed excessive.
For the widest predefined acceptable perioperative systolic blood pressure range (75–145 mmHg pre and postoperatively and 65–135 mmHg during surgery), clevidipine was associated with approximately half the blood pressure excursion associated with nitroglycerin (4.14 vs 8.87 mmHg•min/h, respectively; P=.0006); clevidipine also resulted in significantly less blood pressure excursion versus sodium nitroprusside (4.37 vs 10.50 mmHg•min/h, respectively; P=.0027); there was no significant difference in blood pressure excursions between clevidipine and nicardipine (1.76 vs 1.79 mmHg•min/h, respectively; P=.086), although this comparison was restricted to only the postoperative period.
For the narrowest predefined acceptable perioperative systolic blood pressure range (105–145 mmHg pre and postoperatively and 95–135 mmHg during surgery), clevidipine was superior to sodium nitroprusside in blood pressure excursion (100.17 vs 127.87 mmHg•min/h, respectively; P=.045); clevidipine resulted in a trend towards less excursion compared with nitroglycerin (83.74 vs 108.57 mmHg•min/h, respectively; P=.056).
The rates of the primary clinical end point (a composite of death, stroke, myocardial infarction [MI], and kidney dysfunction) were not significantly different with clevidipine versus its 3 comparators, although the rate of death was significantly lower with clevidipine compared with sodium nitroprusside (1.7% vs 4.7%, respectively; P=.045).
The researchers noted that another important finding from the ECLIPSE study was that tight blood pressure control during the 24-hour perioperative period was associated with lower 30-day mortality compared with wide blood pressure excursions. Thirty-day mortality was increased by 20% with blood pressure excursions >1 mmHg over a 60-minute time period, with the risk increasing with each additional 1-mmHg/min excursion outside the prespecified range. Mortality at 30 days was increased by 43% with a 2-mmHg/min variation from the target range over 60 minutes, 71% with a 3-mmHg/min variation, 105% with a 4-mmHg/min variation, and 146% with a 5-mmHg/min variation.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Sets Goal Date for Lymphoma Drug Columvi
December 5th 2024The combination of Columvi, gemcitabine and oxaliplatin is the first CD20xCD3 bispecific antibody to show positive results in a randomized diffuse large B-cell lymphoma phase 3 trial. The FDA’s decision is expected by July 20, 2025.
Read More